Results 51 to 60 of about 1,443,667 (357)
Leukemia, 2021 Despite significant progress over the last few decades in the treatment of acute myeloid leukemia (AML), there still remains a major unmet medical need for this disease.
R. Ganesan +5 more
semanticscholar +1 more source
Emerging Antibodies in Cancer Therapy
Advanced NanoBiomed Research, 2023 Since the first monoclonal antibody, Orthoclone OKT3, was approved in 1986 for the treatment of acute allograft rejection in renal transplant recipients, the number of antibody‐based therapies has increased remarkably, with more than 130 monoclonal ...
Yaping Sun, Jian Xu
doaj +1 more source
Cancer, Volume 129, Issue 2, Page 255-263, 15 January 2023., 2023 Abstract Background Autologous anti‐CD19 chimeric antigen receptor (CAR) T‐cell therapy is an effective treatment for approximately 40% of relapsed/refractory large B cell lymphomas (LBCL), and early identification of patients at risk for relapse or progression after CAR T‐cell therapy represents a clinical need.
Anna Guidetti +14 more
wiley +1 more source
OncoImmunology, 2018 The redirection of T cell activity using bispecific antibodies is one of the most promising cancer immunotherapy approaches currently in development, but it is limited by cytokine storm-related toxicities, as well as the pharmacokinetics and tumor ...
Seandean Lykke Harwood +16 more
doaj +1 more source
Antibody Representation Learning for Drug Discovery [PDF]
arXiv, 2022 Therapeutic antibody development has become an increasingly popular approach for drug development. To date, antibody therapeutics are largely developed using large scale experimental screens of antibody libraries containing hundreds of millions of antibody sequences.
arxiv
ASAP-SML: An Antibody Sequence Analysis Pipeline Using Statistical Testing and Machine Learning [PDF]
, 2020 Antibodies are capable of potently and specifically binding individual antigens and, in some cases, disrupting their functions. The key challenge in generating antibody-based inhibitors is the lack of fundamental information relating sequences of antibodies to their unique properties as inhibitors.
arxiv +1 more source
Journal for ImmunoTherapy of Cancer, 2021 Background Stimulation of 4-1BB with agonistic antibodies is a promising strategy for improving the therapeutic efficacy of immune checkpoint inhibitors (ICIs) or for overcoming resistance to ICIs.
Seongju Jeong +21 more
semanticscholar +1 more source
mAbs, 2020 The development of antibody therapeutics relies on animal models that accurately recapitulate disease biology. Syngeneic mouse models are increasingly used with new molecules to capture the biology of complex cancers and disease states, and to provide ...
Feng Wang +17 more
doaj +1 more source
Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoimmunity [PDF]
, 2020 Antibodies recognizing complexes of the chemokine platelet factor 4 (PF4-CXCL4) and polyanions (P) opsonize PF4-coated bacteria hereby mediating bacterial host defense. A subset of these antibodies may activate platelets after binding to PF4-heparin complexes, causing the prothrombotic adverse drug reaction heparin-induced thrombocytopenia (HIT).
arxiv +1 more source
In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy
Molecular Therapy: Methods & Clinical Development, 2017 Current therapies against hepatitis B virus (HBV) do not reliably cure chronic infection, necessitating new therapeutic approaches. The T cell response can clear HBV during acute infection, and the adoptive transfer of antiviral T cells during bone ...
Robert L. Kruse +6 more
doaj +1 more source